221 results about "Febuxostat" patented technology

The invention provides a crystal form of anti-hyperuricemia drug 2-(3-cyano-4-isooxyphenyl)-4-methyl-5-thiazole formic acid and a method for preparing the same. The method for preparing the crystal form mainly comprises the following steps: heating up and dissolving the 2-(3-cyano-4-isooxyphenyl)-4-methyl-5-thiazole formic acid in ethyl acetate, and cooling down the solution for recrystallizing the solution to obtain the crystal form. The crystal form has better dissolution degree and stability.

The invention relates to a high bioavailability febuxostat oral solid dosage and a preparation method thereof. The invention is characterized in that the solid dosage comprises: a) febuxostat is C, H, I or J crystal form; b) the average grain diameter of the febuxostat crystal form ranges from 3.5-10mum, preferably 3.5-7mum. The preferable oral solid dosage is tablet, has the advantages of simple preparation technique, low cost and relatively high bioavailability, and can be used for treating diseases relative to extremely-high uric acid, such as gout, and reducing uric acid in blood.

The invention relates to a febuxostat dispersible tablet drug and a preparing method. The drug is prepared from febuxostat as the active drug ingredient, and acceptable auxiliary ingredients in the dispersible tablet preparation. The febuxostat dispersible tablet drug is characterized in that at least one of polyoxyethylene 40 monostearate ingredient, polyethenoxy ether castor oil ingredient and hydrogenated castor oil polyoxyl ingredient in the auxiliary ingredients is used as a solubilizing agent ingredient and has the usage amount of 0.1-5 times the weight of febuxostat. The drug can obviously enhance the dissolution rate of the insoluble effective drug ingredient of febuxostat, and has the advantages of high drug dispersion degree, high dissolution rate, quick absorption and effect taking, high biological utilization degree, and the like.

The invention relates to a febuxostat crystal and a preparation method and medical composite thereof. Characteristic absorption peaks appear on the crystal X-ray powder diffraction pattern at the following reflection angle 2 theta: 4.99 degrees, 6.90 degrees, 11.68 degrees, 15.89 degrees, 17.54 degrees, 24.87 degrees, 25.24 degrees, 25.82 degrees, 26.18 degrees and 26.76 degrees; characteristic absorption peaks appear on the infrared spectrogram when the values of wave number are separately about 3535cm<-1>, 3462 cm<-1>, 2962cm<-1>, 2875cm<-1>, 1681cm<-1>, 825cm<-1>, 765cm<-1> and 727cm<-1>; the grain size distribution range measured by the laser diffraction method is 0.5-50mu m, the statistical grain size D90 is less than 40mu m, and the average grain size is less than 20mu m. The febuxostat crystal can be obtained by recrystallizing febuxostat in N,N-dimethylformamide or N,N-dimethylacetamide. The febuxostat crystal and pharmaceutically acceptable auxiliary components can form the corresponding pharmaceutical preparation for use; the pharmaceutical preparation can have satisfactory dissolution rate; and the dissolution rate in 5 minutes of the tablet in phosphate buffer solution medium with a pH value of 7.2 is not less than 45% and in 35 minute is not less than 95%.

The invention relates to a febuxostat dispersible tablet and a preparation method thereof. The febuxostat dispersible tablet comprises febuxostat as a main material and a diluent, a disintegrant, a binder, a flow aid, a lubricant and other assistants as auxiliary materials, wherein the flow aid is silicone dioxide, and the lubricant is magnesium stearate. The febuxostat dispersible tablet is prepared from the following components in percentage by weight: 5-30% of the febuxostat, 20-80% of the diluent, 5-30% of the disintegrant, 0.1-5% of the binder, 1-10% of the silicone dioxide, 0.2-5% of the magnesium stearate and 2-8% of other assistants. The febuxostat dispersible tablet prepared by adding a proper amount of auxiliary materials into crushed febuxostat has the advantages of rapid and complete drug dissolution and stable quality, is suitable for long-term storage and convenient to use, and the bioavailability of human bodies on drugs is increased so as to increase curative effect.

The invention discloses 2-(3-cyano-4-isobutoxy phenyl)-4-methyl-5-thiazolyl formic acid of a new delta-crystal form and a preparation method thereof. The method comprises the steps of: heating a mixture of Febuxostat and absolute ethanol till completely dissolving, and then filtering to obtain an alcoholate; putting the alcoholate in a 80 DEG C baking oven for baking for 2 hours under 2mmHg vacuum decompression to obtain crystals of the delta-crystal form, which has excellent temperature and humidity stability, no any organic solvents or water and is suitable for preparation process and long-term storage. A medicine composite which takes the compound of the crystal form can be used for reducing uric acid in blood and treating all clinical hyperlithic situations, such as uarthritis.

The invention relates to a medicinal composition for treating hyperuricemia, which comprises Febuxostat or derivate thereof, benzbromarone and a pharmaceutically acceptable medicinal carrier, whereinthe ratio in weight portion of the Febuxostat or derivate thereof to the benzbromarone to the pharmaceutically acceptable medicinal carrier is 1:1-4:0.5-100. The medicinal composition can provide extremely beneficial effects of treating the hyperuricemia. Pharmacological tests prove that the medicinal composition has obviously synergistic action, can quickly reduce the concentration of purine trione in blood serum, remarkably improves effect of treating the hyperuricemia, greatly reduces medicament dosage of single component simultaneously, and effectively reduces toxic and side effect of medicament.

The invention provides an oral slow/controlled-release preparation containing febuxostat and a preparation method thereof, which prepare the febuxostat into the long-acting oral slow/controlled-release preparation and can solve the problem that the incidence of an adverse reaction is increased because of the quicker dissolving-out and the burst effect of a common preparation existing in the prior art. The invention has the technical scheme that the oral slow/controlled-release preparation containing the febuxostat comprises the following components by weight percent: 5 to 60 percent of febuxostat, 10 to 50 percent of slow/controlled-release material, 20 to 80 percent of filling auxiliary material, 0.3 to 20 percent of adhesive and 0.1 to 7 percent of lubricant or glidant. Compared with a common quick-release preparation, the slow/controlled-release preparation can keep the effective and stable blood concentration for a longer time, avoids the burst effect of the quick-release preparation, lowers the incidence of the adverse reaction and enhances the application safety.

The invention relates to a medicine analysis method, and especially relates to a method for determining impurities in febuxostat and its preparation through high performance liquid chromatography. The method for detecting and analyzing impurities in febuxostat is established through treating an octadecylsilane bonded silica gel as a filler and a mixed solution comprising a triethylamine buffer solution and methanol as a mobile phase, and is sensitive, specific and comprehensive. The change of the impurities in the production and storage processes of febuxostat can be effectively detected through adopting the method, so the method is of great practical importance for the quality control of febuxostat and its preparation.

The invention relates to a method for preparing a febuxostat intermediate, which comprises the following steps of: dissolving 2-[4-hydroxyphenyl]-4-methylthiazol-5-ethyl formate in a mixed acid reaction solvent, adding a certain amount of urotropine, heating to react for 1-36 h at certain temperature, and treating the reaction liquid to obtain corresponding heterocyclic aldehyde.

The invention discloses a medicine compound containing febuxostat; and containing the febuxostat and surfactant, the medicine compound can be stably and quickly dissolved out and is applicable to arthrolithiasis curing.

The invention relates to a preparation method of high-purity febuxostat. The method comprises the steps: carrying out etherification reaction on ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate and refined bromo-isobutane, then conducting cyaniding and hydrolysis to obtain other crude febuxostat, and recrystalizing to obtain high-purity febuxostat. In febuxostat prepared by using the method, the content of impurity 2-(3-cyano-4-n-propoxy phenyl)-4-methylthiazole-5-formic acid is smaller than 0.10%.

The invention relates to the field of pharmaceutical chemistry, in particular to a preparation method of 2-(3-formoxyl-4-hydroxy phenyl)-4-methyl-thiazole-5-carboxylate as an intermediate of pharmaceutical febuxostat for treating gout; the invention is characterized in that the intermediate is prepared through the reaction of 2-(4-hydroxy phenyl)-4-methyl-thiazole-5-carboxylate and paraformaldehyde under the catalysis of tin tetrachloride. The preparation method avoids the use of trifluoroacetic acid and methenamine as corrosive reagents, the yield of a formylation reaction of the febuxostat and low toxicity paraformaldehyde in acetonitrile can reach more than 95 percent, and the preparation method is easy for industrialization.

The invention provides a method for synthesizing febuxostat. The method comprises the following steps of: (a) performing aromatic ring substitution reaction on a compound of a formula I to obtain a compound of a formula II; (b) performing halogen-metal exchange reaction on the compound of the formula II to obtain a compound of a formula III; (c) performing coupling reaction on the compound of the formula III and the compound of a formula VI under the action of a metal catalyst to obtain a compound of a formula IV; and (d) performing hydrolysis reaction on the compound of the formula IV to obtain the compound of a formula V, namely febuxostat, wherein X is I or Br; M is selected from boric acid ester or SnBu3; and R is H or an alkyl group. In the method, a convergent synthesis strategy is adopted, and a carbon-carbon bond is formed by applying metal catalyzed aromatic ring coupling reaction in a key step, so that a system in which a benzene ring is coupled with a thiazole ring is established. The method has the advantages of simple and short steps, high yield and low environmental pollution and can be suitable for industrial production.

The invention provides a preparation method of 2-(3-formyl-4-isobutoxy phenyl)-4-methyl thiazole-5-ethyl formate which is obtained by using 4-isobutoxy cyanophenyl as an initial raw material and through a series of reactions. The invention also provides a preparation method of febuxostat, which comprises the following steps: reacting 2-(3-formyl-4-isobutoxy phenyl)-4-methyl thiazole-5-ethyl formate with hydroxylamine hydrochloride under the action of a catalyst to obtain a compound with a structure as shown in formula (VIII); hydrolyzing the compound with the structure as shown in formula (VIII) under an alkaline condition, and performing acidification to obtain febuxostat. The preparation method of the invention prepares febuxostat without using cyanides, and is high in safety. The preparation methods of the invention are simple in operation and high in yield. Experiment results show that the yield of step (A) is up to 90%, the yield of step (B) is up to 85%, the yield of step (C) is up to 90%, the yield of step (D) is up to 90%, and the yield of step (E) is up to 97%.

The invention relates to a medicinal composition for treating hyperuricemia, which comprises Febuxostat or derivate thereof, probenecid and a pharmaceutically acceptable medicinal carrier, wherein theratio in weight portion of the Febuxostat or derivate thereof to the probenecid to the pharmaceutically acceptable medicinal carrier is 1:10-200:0.5-100. The medicinal composition can provide extremely beneficial effects of treating the hyperuricemia. Pharmacological tests prove that the medicinal composition has obviously synergistic action, can quickly reduce the concentration of purine trionein blood serum, remarkably improves effect of treating the hyperuricemia, greatly reduces medicament dosage of single component simultaneously, and effectively reduces toxic and side effect of medicament.

The invention discloses a new crystal form of febuxostat and a preparation method thereof. The preparation method of the crystal form adopts tetrahydrofuran as a solvent, the crystal form is small instatic electricity and has good dissolution rate, other processing manners such as micronization or preparation of solid dispersion and the like are not required during the process of preparing the pharmaceutical preparation, and the preparation with good dissolution rate can be obtained according to the conventional preparation process.

The present invention relates to a solid dispersion system of febuxostat. The solid dispersion system comprises febuxostat and a nanometer skeletal material of colloid silica, and optionally includes a conventional solid dispersion carrier; wherein the conventional solid dispersion carrier is at least one selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone, hydroxypropyl methyl cellulose, sodium alginate, poloxamer and polyacrylic resin. The solid dispersion system can preferably solve the technical problems of febuxostat with poor solubility in water and bioavailability.

The invention relates to a preparation method of important intermediates, such as 2-(3-formaldehyde radical-4-hydroxyl phenyl)-4-methyl-5-thiazole ethyl formate, of Febuxostat. The method is as follows: reacting thioacetamide and 4-cyanol phenol which are used as raw materials in concentrated hydrochloric acid solution to obtain 4-hydroxythiobenzamide; reacting 4-hydroxythiobenzamide with 2-chloracetyl ethyl acetate to prepare 2-(4-hydroxyl phenyl)-4-methyl-5-thiazole ethyl formate; and reacting 2-(4-hydroxyl phenyl)-4-methyl-5-thiazole ethyl formate with hexamethylenetetramine in the presence of polyphosphoric acid and methanesulfonic acid to obtain 2-(3-formaldehyde radical-4-hydroxyl phenyl)-4-methyl-5-thiazole ethyl formate. In the invention, the operation is simple and convenient, the yield is high, the preparation process is stable, and the production cost is low, thus the preparation method is suitable for industrial production and application.

The invention discloses a Febuxostat tablet. The Febuxostat tablet comprises a tablet core and a coating, wherein the tablet core comprises the following components in weight percentage: 5-30 percent of Febuxostat, 15-60 percent of filler, 1-20 percent of disintegrating agent, 0.1-5 percent of surface active agent, 0.1-8 percent of lubricant and a right amount of adhesive. According to the Febuxostat tablet, trough adopting the powerful disintegrating agent within a reasonable proportional region, and meanwhile, through jointly using the surface active agent, the poorly water-soluble drug Febuxostat dissolves out, and further, the dissolvability of the Febuxostat is increased, and the bioavailability of the Febuxostat is improved. Moreover, the Febuxostat tablet is simple in preparation method, controllable in quality and high in stability.

The invention discloses a synthetic method of febuxostat. The synthetic method of febuxostat comprises the following steps: (1) preparing 4-hydroxy-1, 3-phthalic aldehyde; (2) preparing 4-hydroxy-1, 3-diphenyl nitrile; (3) preparing 4-isobutoxy-1, 3-diphenyl nitrile; (4) preparing 2-isobutoxy-5-sulfobenzyl acylamino cyanophenyl; (5) preparing 2-(3-cyan-4-isobutyl phenyl ether)-4-methylthiazole-5-ethyl formate; and (6) preparing febuxostat. According to the synthetic method, the low-price salicylaldehyde is adopted as the starting material and is subjected to aldehydizing, alkylating, thioacid amidating, cyclizing, and hydrolyzing so as to obtain the end product; the toxic agents such as sodium cyanide and the highly-corrosive agent like trifluoroacetic acid are not used; the raw materials in use are low in price and easy to obtain; the reaction condition is mild; the operation is simple and convenient; the total recovery is high; the obtained product is easy to purify; and the industrial production is easy to realize.